EHA 2021 | Predictive value of 18F-FDG-PET radiomics in R/R Hodgkin lymphoma
Julia Driessen, MBBS, University of Amsterdam, Amsterdam, The Netherlands, outlines the predictive value of quantitative 18F-FDG-PET radiomics analysis in patients with relapsed/refractory (R/R) Hodgkin lymphoma. Baseline 18F-FDG-PET was analyzed from R/R classical Hodgkin lymphoma patients from three clinical trials of ICE (ifosfamide-carbplatin-etoposide), ICE plus brentuximab vedotin (BV) or DHAP (dexamethasone-high-dose cytarabine-platinum) and BV. The study reported that the combination of 18F-FDG-PET radiomics and clinical features was able to make a strong prediction model for three-year time to progression and could be used to guide risk-stratified treatment in R/R classical Hodgkin lymphoma. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
